Slow Automation Adoption And Partner Execution Risks May Eventually Support QC Automation Upside

Catalysts

About Rapid Micro Biosystems

Rapid Micro Biosystems provides automated microbial quality control systems and related consumables and services for biopharma and other regulated manufacturing labs.

What are the underlying business or industry changes driving this perspective?

• The installed base of 196 Growth Direct systems and high penetration in cell therapies suggests a foundation for higher consumable usage. However, the company still depends on customers moving from initial validation to broad, enterprise rollouts. This reliance could limit the pace of recurring revenue growth if adoption cycles elongate.
• Automation of QC and the growing complexity of advanced biomanufacturing are driving more conversations and events such as Growth Direct Days in Japan and North America. However, the need for customer validation and integration work could slow the translation of this interest into system placements and related product revenue.
• Supplier negotiations and a potential supply agreement with MilliporeSigma are expected to improve consumable and system cost of goods. However, any delay or shortfall in realizing these savings, together with current low product margins, could restrain the path toward higher gross margins and earnings.
• The collaboration with MilliporeSigma extends reach into pharma, personal care and medical devices and makes Rapid Micro the exclusive provider of related services. However, reliance on a larger partner to drive placements introduces execution risk that could temper expected growth in service revenue and associated margin contribution.
• Management points to visibility into a commercial pipeline extending into 2027 and 2028 and access to a US$25 million credit facility. However, ongoing operating losses and cash usage, combined with the need to meet financial metrics to access future debt tranches, may weigh on the company’s ability to convert long term demand drivers into sustained improvements in net margins and earnings.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Rapid Micro Biosystems compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Rapid Micro Biosystems's revenue will grow by 26.7% annually over the next 3 years.
• The bearish analysts are not forecasting that Rapid Micro Biosystems will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Rapid Micro Biosystems's profit margin will increase from -145.8% to the average US Life Sciences industry of 15.6% in 3 years.
• If Rapid Micro Biosystems's profit margin were to converge on the industry average, you could expect earnings to reach $10.9 million (and earnings per share of $0.21) by about June 2029, up from -$50.1 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 30.6x on those 2029 earnings, up from -1.7x today. This future PE is lower than the current PE for the US Life Sciences industry at 39.2x.
• The bearish analysts expect the number of shares outstanding to grow by 4.43% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.28%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Rapid Micro Biosystems continues to report operating losses, with first quarter 2026 net loss of US$14.3 million and operating expenses of US$14.2 million on US$8 million of revenue. If cost reductions and gross margin initiatives progress more slowly than planned, the company could face sustained pressure on net margins and earnings.
• The business relies heavily on customers completing validation and moving to routine use of Growth Direct systems, and first quarter 2026 validations were 5 compared to 9 in the prior year period. Prolonged or repeated delays in validation activity could slow consumable pull through and service work, affecting revenue and gross margins.
• The long term collaboration with MilliporeSigma is central to expanding placements, consumable volumes and a potential supply agreement. Execution depends on a much larger partner converting funnel into closed deals and reshaping the supply chain, which introduces the risk that expected volume growth and material cost savings do not fully materialize, limiting product margins and overall earnings improvement.
• Rapid Micro Biosystems used US$15 million of cash in the first quarter and ended with US$23 million plus US$25 million of undrawn credit that requires the company to meet financial metrics to access future tranches. If revenue growth, gross margin expansion or expense control fall short, access to this capital could tighten and constrain investment in growth while also keeping interest expense and net losses elevated.
• The investment case leans on long term industry trends such as increased QC automation, reshoring and growth in advanced therapies and new geographies. These demand drivers can be sensitive to regulatory changes, macro conditions and capital spending cycles, and any prolonged slowdown or deferral of QC automation projects could weigh on system placements, recurring revenue and the path to higher net margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Rapid Micro Biosystems is $5.0, which represents up to two standard deviations below the consensus price target of $6.67. This valuation is based on what can be assumed as the expectations of Rapid Micro Biosystems's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0, and the most bearish reporting a price target of just $5.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $70.0 million, earnings will come to $10.9 million, and it would be trading on a PE ratio of 30.6x, assuming you use a discount rate of 8.3%.
• Given the current share price of $1.76, the analyst price target of $5.0 is 64.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.